Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now small index

Neuromodulation clinical trials

5 of 5 indexed Neuromodulation trials are currently recruiting.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 5 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Neuromodulation: 5 US clinical trials tracked, 5 recruiting.

Neuromodulation is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. The most active sponsor is Jill M. Wecht, Ed.D., running 1 of these trials.

Enrollment posture brief

Registry condition neuromodulation

OPEN 5 | RECR 100% | LATE 0 | EARLY 0 | RANK #3391 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Neuromodulation (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Neuromodulation

Neuromodulation lists 5 open slots (100% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Neuromodulation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Neuromodulation is recruiting above its size-band peers.

    5 of 5 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Neuromodulation research.

    Jill M. Wecht, Ed.D. accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Neuromodulation trials plan to enrol fewer than 100 people.

    Median target enrolment is 50 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.

  4. Neuromodulation research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase Distribution

Phase data not available

Named interventions

Most-linked intervention names on Neuromodulation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Focused ultrasound neuromodulation Device
1 trials
Focused Ultrasound Neuromodulation - Sham Control Device
1 trials
Auricular Vagal Nerve Stimulation Device
1 trials
Epidural Spinal Stimulation (ESS) Device
1 trials
Transcutaneous Spinal cord Stimulation Device
1 trials
Digitimer Device
1 trials
Deep Brain Stimulation Device
1 trials

US sites by state

Facility locations filed on Neuromodulation trials. A trial with sites in several states counts in each.

Texas 2 trials
New York 2 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Neuromodulation page

5 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neuromodulation condition card totals 5 registered trials; most-linked intervention Focused ultrasound neuromodulation; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.